Blood clearance and activity of erythrocyte-coupled fibrinolytics

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 3, 2005, Pages 1106-1113

  Ganguly, Kumkum ^a   Krasik, Tatiana ^a   Medinilla, Sandra ^a   Bdeir, Khalil ^b   Cines, Douglas B ^b   Muzykantov, Vladimir R ^a,b   Murciano, Juan Carlos ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Research Center   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRIN; PLASMINOGEN ACTIVATOR; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CIRCULATION; CIRCULATION TIME; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME REGULATION; ERYTHROCYTE; ERYTHROCYTE KINETICS; FIBRIN CLOT; FIBRINOLYSIS; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; ERYTHROCYTES; FIBRIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; METABOLIC CLEARANCE RATE; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 14344252453     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.075770     Document Type: Article

References (38)

1. Bax BE, Bain MD, Fairbanks LD, Webster AD, and Chalmers RA (2000) In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. Br J Haematol 109:549-554.
2. Benchenane K, Lopez-Atalaya JP, Fernandez-Monreal M, Touzani O, and Vivien D (2004) Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 27:155-160.
3. Benedict CR, Befino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, and Bennett WF (1995) New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 92:3032-3040.
4. Bu G, Williams S, Strickland DK, and Schwartz AL (1992) Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 89:7427-7431.
5. Clagett GP, Anderson FA Jr, Heit J, Levine MN, and Wheeler HB (1995) Prevention of venous thromboembolism. Chest 108:312S-334S.
6. Collen D and Lijnen HR (2004) Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2:541-546.
7. Feigen LP, Nicholson NS, King LW, Campion JG, Tjoeng FS, and Panzer-Knodle SG (1993) SC-49992, a mimetic of the peptide arginine-glycine- aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 267:1191-1197.
8. Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RA, and Friedman PA (1989) Isolation, characterization and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 264:17947-17952.
9. Hennan JK, Hong TT, Shergill AK, Driscoll EM, Cardin AD, and Lucchesi BR (2002) Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther 301:1151-1156.
10. Hirsh J and Hoak J (1996) Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation. 93:2212-2245.
11. Holvoet P, Dewerchin M, Stassen JM, Lijnen HR, Tollenaere T, Gaffney PJ, and Collen D (1993) Thrombolytic profiles of clot-targeted plasminogen activators: parameters determining potency and initial and maximal rates. Circulation 87:1007-1016.
12. Ihler GM, Glew RH, and Schnure FW (1973) Enzyme loading of erythrocytes. Proc Natl Acad Sci USA 70:2663-2666.
13. Jackson CV, Frank JD, Craft TJ, Sundboom JL, and Smith GF (1992) Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis. J Pharmacol Exp Ther 260:64-70.
14. Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoeff EJ, Stern A, Opitz U, Martin U, Lill H, Prinz H, Lechner M, et al. (1992) Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 5:93-100.
15. Lam SC, Dieter JP, Strebel LC, Taylor TM, Muscolino G, Feinberg H, and Brpaon Le GC (1991) Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents. J Pharmacol Exp Ther 259:1371-1378.
16. Lijnen HR, van Hoef B, Beelen V, and Collen D (1994) Characterization of the murine plasma fibrinolytic system. Eur J Biochem 224:863-871.
17. Lynch JJ Jr, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ, et al. (1995) Nonpeptide glycoprotein IIb/IIIa inhibitors: V. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 272:20-32.
18. Magnani M, Rossi L, Fraternale A, Bianchi M, Antonelli A, Crinelli R, and Chiarantini L (2002) Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther 8:749-751.
19. Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, and Strein K (1991) Pharmacokinetic properties of an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. Thromb Res 62:137-146.
20. Murciano JC, Harshaw D, Neschis DG, Koniaris L, Bdeir K, Medinilla S, Fisher AB, Golden MA, Cines DB, Nakada MT, et al. (2002) Platelets inhibit the lysis of pulmonary microemboli. Am J Physiol Lung Cell Mol Physiol 282:L529-L539.
21. Murciano JC, Medinilla S, Eslin D, Atochina E, Cines DB, and Muzykantov VR (2003) Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol 21:891-896.
22. Muzykantov VR and Murciano JC (1996) Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats. Biotechnol Appl Biochem 24:41-45.
23. Muzykantov VR and Murciano JC (2003) Streptavidin-mediated coupling of therapeutic proteins to the carrier erythrocytes in Erythrocyte engineering for drug delivery and targeting (Magnani M ed) 4 pp 37-67, Kluwer Academic/Plenum Publishers, New York.
24. Muzykantov VR, Murciano JC, Taylor RP, Atochina EN, and Herraez A (1996) Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Anal Biochem 241:109-119.
25. Muzykantov VR, Smirnov MD, and Samokhin GP (1991) Avidin attachment to biotinylated erythrocytes induces homologous lysis via the alternative pathway of complement. Blood 78:2611-2618.
26. Muzykantov VR and Taylor RP (1994) Attachment of biotinylated antibody to red blood cells: antigen-binding capacity of immunoerythrocytes and their susceptibility to lysis by complement. Anal Biochem 223:142-148.
27. Noble S and McTavish D (1996) RPAeplase: a review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 52:589-605.
28. Ouriel K (2003) Thrombi: beware of red cells bearing gifts. Nat Biotechnol 21:871-872.
29. Rijken DC, Groeneveld E, and Barr P, and At-Bergshoeff MM (1994) In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma. Thromb Haemost 72:906-911.
30. Romson JL, Bush LR, Haack DW, and Lucchesi BR (1980) The beneficial effects of oral ibuprofen on coronary artery thrombosis and myocardial ischemia in the conscious dog. J Pharmacol Exp Ther 215:271-278.
31. Sakharov DV and Rijken DC (1995) Superficial accumulation of plasminogen during plasma clot lysis. Circulation 92:1883-1890.
32. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, et al. (2000) Survival outcomes 1 year after reperfusion therapy with either alteplase or rPAeplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation 102:1761-1765.
33. Tsirka SE, Gualandris A, Amaral DG, and Strickland S (1995) Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature (Lond) 377:340-344.
34. Verstraete M, Bounameaux H, de Cock F, Van de Werf F, and Collen D (1985) Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 235:506-512.
35. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, and Lo EH (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313-1317.
36. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, and Lipton SA (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4:228-231.
37. Wooster MB and Luzier AB (1999) RPAeplase: a new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother 33:318-324.
38. Zaltzman AB, Van den Berg CW, Muzykantov VR, and Morgan BP (1995) Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor. Biochem J 307 (Pt 3):651-656.